Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Gobbini, Elisa; Ezzalfani, Monia; Dièras, Véronique; Bachelot, Thomas; Brain, Étienne; Debled, Marc; Jacot, William; Mouret-Reynier, Marie-Ange; Gonçalvès, Anthony; Dalenc, Florence; Patsouris, Anne; Ferrero, Jean Marc; Lévy, Christelle; Lorgis, Véronique; Vanlemmens, Laurence; Lefeuvre-Plesse, Claudia; Mathoulin‐Pélissier, Simone; Petit, Thierry; Uwer, Lionel; Jouannaud, Christelle; Leheurteur, Marianne; Lacroix-Triki, Magali; Cleaud, Audrey Lardy; Robain, Mathieu; Courtinard, Coralie; Cailliot, Christian; Pérol, David; Delaloge, Suzette

doi:10.1016/j.ejca.2018.03.015

Cited by 224 publications

(179 citation statements)

References 24 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…Metastatic cancers are not curable, even if long survivals are now achievable. 8 Worldwide, opinions differ on the impact of organized mammographic screening on the incidence of advanced breast cancers. While some countries have experienced a significant decrease of advanced breast cancers since the beginning of organized mammographic screening, [9][10][11][12][13] many studies have reported that the incidence of advanced stages remained stable, whereas the incidence of early breast cancers increased.…”

Section: Introductionmentioning

confidence: 99%

Modifiable risk factors for advanced vs. early breast cancer in the French E3N cohort

Veron

Gélot

Gusto

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Advanced breast cancer (BC) is associated with heavier treatments and poorer prognosis than early BC. Despite mammographic screening, advanced BC incidence remains stable. Little is known about risk factors differentially associated with advanced BC. We analyzed factors predicting for postmenopausal advanced vs. early BC in the E3N cohort. E3N has been prospectively following 98,995 French women aged 50–65 years at baseline since 1990. Hazard ratios (HRs) and 95% confidence intervals (CIs) for advanced and early invasive BC were estimated with multivariate Cox competing risk hazard models. With a median follow‐up of 15.7 years, 4,941 postmenopausal BC were diagnosed, including 1,878 (38%) advanced BC. Compared to early BC, advanced BC was differentially associated with excess weight (HR 1.39 [95% CI = 1.26–1.53] vs. 1.08 [95% CI = 1.00–1.17], phomogeneity < 0.0001) and living in a rural area (HR 1.14 [95% CI = 1.00–1.31] vs. 0.93 [95% CI = 0.82–1.04], phomogeneity 0.02). Excess weight was the only differential risk factor for advanced BC for hormone‐dependent BC and for women compliant with screening recommendations. Previous mammography was associated with reduced advanced BC risk (HR 0.86 [95% CI = 0.73–1.00]) and increased early BC risk (HR 1.36 [95% CI = 1.18–1.56], phomogeneity < 0.0001), but only for hormone‐dependent BC. Excess weight appears to be mostly associated with advanced BC, especially hormone‐dependent BC. These results add to the evidence for maintaining weight within the recommended limits.

show abstract

Section: Introductionmentioning

confidence: 99%

Modifiable risk factors for advanced vs. early breast cancer in the French E3N cohort

Veron

Gélot

Gusto

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…TNBC je agresivním podtypem karcinomu prsu, který je charakteristický vysokým rizikem relapsu a časným metastazováním. Prognóza pacientek s metastatickým TNBC je špatná, OS se pohybuje kolem 18 měsíců a méně [8]. Snahou je proto v rámci léčby časného karcinomu prsu použít co možná nejefektivnější léčbu.…”

Section: úVodunclassified

Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations – A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno

Holánek¹,

Bílek²,

Nenutil³

et al. 2019

Klin Onkol

View full text Add to dashboard Cite

Východiska: Mutace v genech BRCA1 a BRCA2 je spojená s vysokým rizikem vzniku karcinomu prsu. U onemocnění vznikajících na podkladě této mutace se předpokládá větší efektivita platinových derivátů. Jejich role a účinnost ve smyslu zvýšení pravděpodobnosti patologické kompletní remise (pathological complete remission-pCR) v rámci systémové neoadjuvantní chemoterapie karcinomu prsu u pacientek s BRCA1 a BRCA2 mutací je opakovaně diskutována, nicméně neexistují jednoznačná doporučení. Soubor pacientů a metody: Na souboru pacientek s BRCA1/2 mutovaným nádorem prsu léčených v letech 2010-2017 neoadjuvantní chemoterapií retrospektivně hodnotíme přínos přidání platinového derivátu na dosažení pCR. Odpověď na neoadjuvantní chemoterapii byla hodnocena patologem z definitivního resekátu. Jako pCR byl označen stav, kdy došlo k úplnému vymizení invazivního karcinomu z prsu a event. spádových lymfatických uzlin. Výsledky: V celkovém souboru 76 pacientek (medián 39 let, 62 % triple negativní karcinom (triple negative breast cancer-TNBC), 70% BRCA1 pozitivita) bylo platinovým derivátem léčeno 37 nemocných. Pacientky léčené platinovým derivátem měly signifikantně častěji pCR (57 vs. 23 %, p = 0,005). Pacientka s platinovým režimem má 4,4krát větší šanci na dosažení pCR než pacientka bez platinového režimu za předpokladu stejného fenotypu tumoru (TNBC nebo SR+/ HER2−). Závěr: Neoadjuvantní chemoterapie s platinovým derivátem je u pacientek s BRCA1/2 mutací spojena s vyšší pravděpodobností dosažení pCR, která má důležitý vztah k další prognóze pacientky. Zvažována by měla být především u pacientek s TNBC fenotypem. Klíčová slova karcinom prsu-geny BRCA1-geny BRCA2-neoadjuvantní terapie-cisplatina-karboplatina-patologická kompletní remise Práce byla podpořena Ministerstvem zdravotnictví České republiky-Koncepční rozvoj výzkumné organizace (MMCI 00209805). Práce byla podpořena projektem Ministerstva školství, mládeže a tělovýchovy České republiky (NPU I-LO1413).

show abstract

“…The incidence of TNBC, the most aggressive type of breast cancer with shorter OS, is approximately 15%‐20% of all breast cancers 1‐3 . There are few or no remarkable therapeutic improvements for TNBC, particularly for patients with mTNBC 1‐5 .…”

Section: Introductionmentioning

confidence: 99%

Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer

et al. 2020

View full text Add to dashboard Cite

We undertook an early phase II study of mixed 19‐peptide cancer vaccine monotherapy for 14 advanced metastatic triple‐negative breast cancer (mTNBC) patients refractory to systemic chemotherapy to develop a new type of cancer vaccine. The treatment protocol consisted of a weekly vaccination for 6 weeks, and there were no severe adverse events related to the vaccination throughout the trial. Increase of peptide‐specific IgG against the vaccinated human leukocyte antigen‐matched peptides, but not against the nonmatched peptides, was positively correlated with overall survival (OS) (P < .01). The median OS was 11.5 or 24.4 months in all 14 patients or the 10 patients who completed the vaccination. The patients with lower C‐reactive protein levels or 3 or fewer systemic chemotherapies were favorable candidates for this treatment. Advancement of this therapy to the next stage of study could be warranted based on the safety and immune boosting determined herein (clinical trial registration number: UMIN000014616).

show abstract

Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort

Cited by 224 publications

References 24 publications

Modifiable risk factors for advanced vs. early breast cancer in the French E3N cohort

Modifiable risk factors for advanced vs. early breast cancer in the French E3N cohort

Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations – A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno

Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer

Contact Info

Product

Resources

About